Q-omics provides the consensus-scored CICP26 profile across patient tissues and cancer cell-line models. CICP26 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CICP26 is differentially expressed in 6, with the highest sampling consensus in ESCA. Additionally, CICP26 RNA expression shows 7,529 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, ESCA, and TGCT as cancer lineages where CICP26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CICP26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CICP26 survival associations across molecular data types. CICP26 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CICP26 RNA expression–survival associations across cancer types. High CICP26 expression shows unfavorable associations in KIRC, LUSC, ACC, UVM and PAAD, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for CICP26 RNA expression.
This table summarizes CICP26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for CICP26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CICP26 shows lower tumor expression in ESCA, THCA, COAD and LIHC and higher tumor expression in LUSC and KICH. The ESCA box plot shows higher CICP26 RNA expression in normal versus tumor tissue (log2 FC = −0.059, t-test p = .013).
This table shows molecular features associated with CICP26 in patient tissues and cancer cell lines. In patient samples, CICP26 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
